



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

007 98115

Reagent: vDK1

Catalog Number: 800

Lot Number:

Provided: 1 ml of vaccinia virus lysate. Titer = $10^{8.75}$ TCID₅₀/ml. Infects mammalian cells.

Cloning Vector: Vaccinia virus, WR strain.

Description: Contains the entire coding region of HIV-1 *gag* beginning at nucleotide 716 and two-thirds of the coding region of pro, ending at nucleotide 2428. No LTR sequences are included. Expression is driven by the vaccinia early-late 7.5 kD promoter. A 1700 bp *Bss*HI-*Bcl*I restriction fragment containing the HIV-1 *gag* gene from the molecular clone pHXB2.gpt (provided by Dr. A. Aldovini, Whitehead Institute) was inserted into the *Sma*I site of pSC11 (provided by Dr. B. Moss, NIAID) by blunt-end ligation, so that *gag* was positioned downstream of the vaccinia 7.5 kD promoter. The resulting plasmid, pDK1, was then used to insert the *gag* gene into the vaccinia TK gene by homologous recombination.¹ Contains a β -Gal marker.

Special Characteristics: Virus stocks were prepared in TK-143 cells. On Western blots probed with an anti-p24 monoclonal antibody, 55 kD and 41 kD proteins are detected. Supernatants of infected cells contain in excess of 200 ng/ml of p24 antigen. EBV-transformed lymphoblasts infected with vDK1 can serve as targets for HIV-*gag*-specific cytotoxic T cells.² Sterility: Negative for bacteria, fungi, and mycoplasma. Cloning Site: Cloned into vaccinia thymidine kinase (TK) gene downstream of the vaccinia 7.5 kD promoter.

Recommended Storage: -70degreeC.

Contributor: Dr. Daniel R. Kuritzkes.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References: ¹Chakrabarti, S., et al., Vaccinia virus expression vector: Coexpression of β -galactosidase provides visual screening of recombinant virus plaques. *Mol Cell Biol* **5**:3403-3409, 1985.
²McFarland EJ, et al. HIV-1 Gag- and RT-specific cytotoxic T cell lines derived from a perinatally infected child. *J Infect Dis* **167**:719-723, 1993.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: vDK1 from Dr. Daniel R. Kuritzkes." Also include the references cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Sally Hu at the NIH Office of Technology Transfer, Email: hus@mail.nih.gov, Phone: 301-435-5606, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated: June 24, 2013

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.